

We thank the reviewers for their very contributive suggestions.

All of the revisions that we made to the revised manuscript are highlighted in yellow in the updated version of the manuscript.

Reviewer #1: The article is very comprehensive and adequately highlights the differences between a guideline set forth by a national and an international liver society. There are several typographical errors throughout the manuscript and thus will need polishing.

We corrected typographical errors and tried to polish the manuscript.

Reviewer #2: The editorial is well written, very interesting and highlights the main issues of DAA treatment in the French population. Some revisions are to be made: AFEF considers the combination ombitasvir paritaprevir/ritonavir obsolete, but in many geographic areas this combination stays as a very good option, as studies from real life demonstrate the efficacy and safety of this combination in chronic hepatitis C, even in people with compensated liver cirrhosis. This study may be cited: Preda CM, Popescu CP, Baicus C, et al. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int Aug 2018 Apr; 38(4). 602-610 doi: 10.1111/liv.13550

We added this sentence and the reference thank you.

Although this is an editorial about AFEF recent hepatitis C guidelines, in the References part there is no reference from AFEF guidelines or maybe I did not observe it.

The reference has been added.

There are many typographical errors: for example: Page 3: instead of "severe" F2 fibrosis "severe" F3-4 fibrosis

In fact no, the indication was really a subgroup of patients with a severe F2 fibrosis. As this concept is not classic, we prefer to delete it for a better understanding.

Page 3: ombitasvir paritaprevir/ritonavir instead of ombistasvir paritaprevir/ritonavir Page 9:

HEPATITIS C instead of HEPATITE C Page 11: Decompensated instead of Decomensated Page 4, last sentence should be "in the experimental stage", page 5, second paragraph "the key", third paragraph "to identify", page 6, second half of the page "A simple evaluation of the drug interactions is easy to do,", page 7, second paragraph "focusing on the recommendations of pangentotypic associations"

Typographical errors have been corrected.

Overall, it is a good editorial that should be published and I find Table 1 a very good one, interesting and useful for medical practice.

Reviewer #3: This is an interesting editorial by an established author in the field of hepatology The treatment of hepatitis C has seen exponential growth in the latter half of this past decade The authors provides contrast between the state of the art international position of EASL guidelines and an Avante Garde approach from AFEF which is tailored to meet unique needs of the French Hepatitis C position. This is a high quality editorial which is well written and provides an interesting perspective. I have made a few minor suggestions for the author's consideration.

They will find these suggestions as reviewer's comments in the attached Manuscript

We thank the reviewer for the suggestions and added sentences to argument the points underlined in the comments.